CHARLES SCHWAB INVESTMENT MANAGEMENT INC - NEUBASE THERAPEUTICS INC ownership

NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 58 filers reported holding NEUBASE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of NEUBASE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$5,497
-2.7%
29,7160.0%0.00%
Q4 2022$5,652
-52.9%
29,7160.0%0.00%
Q3 2022$12,000
-62.5%
29,7160.0%0.00%
Q2 2022$32,000
-57.9%
29,716
+89.0%
0.00%
Q2 2021$76,000
-75.1%
15,720
-61.8%
0.00%
Q1 2021$305,000
+5.9%
41,1580.0%0.00%
Q4 2020$288,000
-8.0%
41,1580.0%0.00%
Q3 2020$313,000
-18.1%
41,158
-5.3%
0.00%
Q2 2020$382,00043,4720.00%
Other shareholders
NEUBASE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Greenlight Capital 2,027,027$14,169,0000.85%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 103,500$723,0000.55%
Sio Capital Management, LLC 293,699$2,053,0000.42%
GSA CAPITAL PARTNERS LLP 121,389$849,0000.14%
Frontier Wealth Management LLC 145,000$1,014,0000.08%
PRELUDE CAPITAL MANAGEMENT, LLC 311,000$2,174,0000.06%
Oak Grove Capital LLC 19,175$134,0000.04%
PREMIER ASSET MANAGEMENT LLC 14,977$105,0000.02%
Trexquant Investment LP 15,479$108,0000.01%
PILLAR PACIFIC CAPITAL MANAGEMENT LLC 19,800$138,0000.01%
View complete list of NEUBASE THERAPEUTICS INC shareholders